Viveca Ritsinger1, Eleni Tanoglidi2, Klas Malmberg3, Per Näsman4, Lars Rydén3, Åke Tenerz2, Anna Norhammar3. 1. Cardiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden Unit for Research and Development Kronoberg County Council, Växjö, Sweden viveca.ritsinger@ki.se. 2. Department of Medicine and Centre for Clinical Research, Central Hospital Västerås, Västerås, Sweden. 3. Cardiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. 4. Centre for Safety Research, KTH Royal Institute of Technology, Stockholm, Sweden.
Abstract
OBJECTIVE: To investigate long-term prognostic importance of newly discovered glucose disturbances in patients with acute myocardial infarction (AMI). METHODS: During 1998-2001, consecutive patients with AMI (n = 167) and healthy controls (n = 184) with no previously known diabetes were investigated with an oral glucose tolerance test (OGTT). Patients and controls were separately followed up for cardiovascular events (first of cardiovascular mortality/AMI/stroke/heart failure) during a decade. RESULTS: In all, 68% of the patients and 35% of the controls had newly detected abnormal glucose tolerance (AGT). Cardiovascular event (n = 72, p = 0.0019) and cardiovascular mortality (n = 31, p = 0.031) were more frequent in patients with newly detected AGT. Regarding patients, a Cox proportional-hazard regression analysis identified AGT (hazard ratio (HR): 2.30; 95% confidence interval (CI): 1.24-4.25; p = 0.008) and previous AMI (HR: 2.39; CI: 1.31-4.35; p = 0.004) as prognostically important. CONCLUSION: An OGTT at discharge after AMI disclosed a high proportion of patients with previously unknown AGT which had a significant and independent association with long-term prognosis.
OBJECTIVE: To investigate long-term prognostic importance of newly discovered glucose disturbances in patients with acute myocardial infarction (AMI). METHODS: During 1998-2001, consecutive patients with AMI (n = 167) and healthy controls (n = 184) with no previously known diabetes were investigated with an oral glucose tolerance test (OGTT). Patients and controls were separately followed up for cardiovascular events (first of cardiovascular mortality/AMI/stroke/heart failure) during a decade. RESULTS: In all, 68% of the patients and 35% of the controls had newly detected abnormal glucose tolerance (AGT). Cardiovascular event (n = 72, p = 0.0019) and cardiovascular mortality (n = 31, p = 0.031) were more frequent in patients with newly detected AGT. Regarding patients, a Cox proportional-hazard regression analysis identified AGT (hazard ratio (HR): 2.30; 95% confidence interval (CI): 1.24-4.25; p = 0.008) and previous AMI (HR: 2.39; CI: 1.31-4.35; p = 0.004) as prognostically important. CONCLUSION: An OGTT at discharge after AMI disclosed a high proportion of patients with previously unknown AGT which had a significant and independent association with long-term prognosis.
Authors: Sara Meziani; Giulia Ferrannini; Mette Bjerre; Troels K Hansen; Viveca Ritsinger; Anna Norhammar; Viveca Gyberg; Per Näsman; Lars Rydén; Linda G Mellbin Journal: Cardiovasc Diabetol Date: 2022-07-08 Impact factor: 8.949
Authors: Bahira Shahim; Viveca Gyberg; Dirk De Bacquer; Kornelia Kotseva; Guy De Backer; Oliver Schnell; Jaakko Tuomilehto; David Wood; Lars Rydén Journal: Cardiovasc Diabetol Date: 2018-01-24 Impact factor: 9.951
Authors: Bahira Shahim; Dirk De Bacquer; Guy De Backer; Viveca Gyberg; Kornelia Kotseva; Linda Mellbin; Oliver Schnell; Jaakko Tuomilehto; David Wood; Lars Rydén Journal: Diabetes Care Date: 2017-06-21 Impact factor: 19.112
Authors: Viveca Ritsinger; Bo Lagerqvist; Pia Lundman; Emil Hagström; Anna Norhammar Journal: Diab Vasc Dis Res Date: 2020 Nov-Dec Impact factor: 3.291
Authors: Viveca Gyberg; Dirk De Bacquer; Kornelia Kotseva; Guy De Backer; Oliver Schnell; Jaakko Tuomilehto; David Wood; Lars Rydén Journal: BMJ Open Date: 2016-12-08 Impact factor: 2.692